Presentation at the 2022 World Vaccine Congress entitled “Novel DNA Approaches for Cancer Immunotherapies and Multivalent Infectious Disease Vaccines” by Dr. Khursheed Anwer, Celsion’s Chief Science Officer
April 21, 2022
“Phase Ib Trial Efficacy Estimates via a Clinical Trial Synthetic Control Arm” at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, LA
April 14, 2022
Poster Presentation at Society of Gynecologic Oncology (SGO) Virtual Annual Meeting on Women’s Cancer_March 19-26, 2021
March 30, 2021
Expert Call – Ovarian Cancer Treatment Landscape and Emerging Opportunities Oppenheimer & Co. Inc. Conference Call
August 8, 2019
Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium Entitled “Phase I study of IL-12 plasmid administered in combination with NAC in patients with advanced stage ovarian cancer” by Dr. Premal H. Thaker, M.D., M.S.
March 4, 2019
Publication in Future Oncology – GEN-1 immunotherapy for the treatment of ovarian cancer, Premal H. Thaker, Nicholas Borys, Jason Fewell & Khursheed Anwer
October 22, 2018
KoL Lunch Presentation by Dr. Premal Thaker titled “Ovarian Cancer: New Horizons and Treatments”
March 1, 2018
Presentation at the American Association of Cancer Research (AACR) Special Conference entitled "Addressing Critical Questions in Ovarian Cancer Research and Treatment" by Dr. Khursheed Anwer, Celsion's executive vice president and chief scientific officer
October 2, 2017
Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Phase I st
February 23, 2017
Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Immunologic
February 23, 2017
Presentation at the 2016 American Association of Cancer Research (AACR) Annual Meeting during the Drug Delivery Session by Dr. Jason Fewell entitled "Interlukin-12 Gene therapy in Combination with Bevacizumab and PEGylated Liposomal Doxorubicin for Treatm
April 18, 2016
A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Pegylated Liposomal Doxorubicin) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Pr
June 1, 2015
Presentation at the Molecular Medicine TRI-Conference on February 20, 2015 by Dr. Khursheed Anwer titled "Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer."
February 20, 2015